ProCE Banner Activity

Phase II DESTINY-CRC01: Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer

Slideset Download
Conference Coverage
In patients with previously treated HER2+ metastatic CRC, T-DXd associated with a response rate of 45% and durable responses.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono